Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Gut

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 1 · 16.7%High 4 · 66.7%

Failure to induce clinical remission at end of study · Patients with quiescent ulcerative colitis

Tofacitinib leads to lower failure to achieve clinical remission (5 mg/10 mg) compared with placebo (high certainty).

1 finding from 1 review

Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.7 [0.64, 0.77]
1 study · 593 participants
High

Failure to maintain clinical response · Patients with quiescent ulcerative colitis

Tofacitinib leads to lower failure to maintain clinical response (5 mg/10 mg) compared with placebo (high certainty).

1 finding from 1 review

Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.54 [0.47, 0.62]
1 study · 593 participants
High

Failure to induce endoscopic remission · Patients with quiescent ulcerative colitis

Tofacitinib leads to lower failure to achieve endoscopic remission (5 mg/10 mg) compared with placebo (high certainty).

1 finding from 1 review

Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.88 [0.83, 0.92]
1 study · 593 participants
High

Adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis

Tofacitinib showed no clear difference in adverse events (5 mg/10 mg) compared with placebo (high certainty).

1 finding from 1 review

Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.01 [0.92, 1.11]
1 study · 592 participants
High

Serious adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis

Tofacitinib showed no clear difference in serious adverse events (5 mg/10 mg) compared with placebo (low certainty).

1 finding from 1 review

Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.81 [0.42, 1.59]
1 study · 592 participants
Low

Withdrawals due to adverse events · Patients with quiescent ulcerative colitis

Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).

1 finding from 1 review

Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.5 [0.33, 0.77]
1 study · 592 participants
Moderate